This study provides the first demonstration of both GPCR agonism and antagonism by de novo designed full-length IgG antibodies, demonstrating that the technology can deliver antibodies with programmable function and key properties expected of lead candidates, opening opportunities for first-in-class therapeutics agains...
R. Aglietti, Ramin Ansari, Peter M. Bowers et al.· bioRxiv· 0 citations
Protein engineering appears to be entering a golden age, defined by a rapidly accelerating pace of progress, even as significant challenges in design, screening, and real-world application remain.
H. Ai, Frances H. Arnold, Doug Barrick et al.· Protein engineering, design...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.